Since the PDE inhibitors and ibudilast in particular may act in an anti-inflammatory manner by inhibiting MIF, TNF-α and TLR-4, they have been suggested to represent an attractive candidate for MS treatment. This evidence concerns the gene TNF and myeloid sarcoma.